Charley'S Fund Inc

“Benjamin seckler, md (board chairman), is husband to tracy kramer seckler (board member). Earl kramer (treasurer), is father to tracy kramer seckler (board member).”

“Tracy seckler (director) reviewed and approved the draft 990 which was made final upon her approval.”

“Officers, directors and key employees must review the policy annually and sign a declaration that they have complied with the policy.”

“Compensation of top management and officers of the organization is developed in consideration of performance and review of relevant competitive benchmarks and submitted to finance board members for approval.”

“The organization makes its governing documents, conflict of interest policy and financial statements available to the public upon request.”

“Importantly, amplify the impact of that funding with strategic problem-solving support to both awardees and the broader dmd research community. To beat dmd, it's not enough to find the best research; we also much proactively identify and knock down hurdles that stand in the way of efficient drug development. Since inception, we have directed more than $50m in funding to these efforts, leveraging both our own funding as well as funding from other dmd patient organizations to identify and support the best science in pursuit of treatments and a cure for dmd. In 2024, we dedicated a total of $453,890 to our programmatic efforts. Of this, $421,730 was dedicated to grants and allocations, and $32,160 was dedicated to other programmatic expenses.”

“We continued our support of the duchenne program at umass medical school, which we created in 2018. The program is powered by a unique collaboration among the medical, research, and patient communities. Founding clinic director dr. Brenda wong, host institution umass medical center and medical school, and charley's fund work jointly to ensure that the duchenne program the largest dedicated duchenne clinic in the northeast us delivers world-class results on three key goals: 1 deliver comprehensive, integrated care to patients 2 host cutting-edge clinical trials 3 drive original research and discoveries to power the next wave of breakthroughs the duchenne program, now in its sixth year, has nearly 400 patients in its direct care and continues to benefit patients worldwide even if they do not enter its doors in person through sponsored clinical trials, original research, and sharing best practices in research and care with the broader community.”